Trial Profile
A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Pimavanserin (Primary)
- Indications Alzheimer's disease; Delusions; Frontotemporal dementia; Hallucinations; Lewy body disease; Parkinson's disease; Vascular dementia
- Focus Registrational; Therapeutic Use
- Acronyms ACP-103-045; HARMONY
- Sponsors Acadia Pharmaceuticals
- 01 Feb 2024 Results of subgroup analysis assessing the effect of pimavanserin on psychosis in the PD dementia, published in the Parkinsonism and Related Disorders
- 18 Sep 2022 Results of pooled analysis of 3 6-week studies (012, 014, and 020) and subgroup of PD dementia (PDD) patients from HARMONY assessing motor and cognition-related safety in pimavanserin-treated patients with Parkinson's Disease Psychosis, presented at the 26th International Congress of Parkinson's Disease and Movement Disorders.
- 04 Aug 2022 Results of post-hoc sub-group analysis assessing efficacy and safety of pimavanserin in patients with Alzheimer's dementia psychosis, presented at the Alzheimer's Association International Conference 2022.